USFDA Gives Green Signal to Levofloxacin

USFDA Gives Green Signal to LevofloxacinDrug firm, Strides Arcolab has revealed that the US Foods and Drug Administration (USFDA) has given approval to the launch of its Levofloxacin injections. These injections are synthetic fluoroquinolone antibiotic and are available in the American market.

This is the second approval received by the Sagent Strides LLC, which is a joint venture between Strides Arcolab and Sagent Pharmaceuticals. At present, Strides is developing and supplying more than 25 injectable products for the USA market, which will be marketed by the Sagent.

Strides Arcolab said in a statement that these injections are available in strengths of 25 mg/mL, packaged in 500mg/20 mL and 750mg/30 mL single-use vials. Levofloxacin is a synthetic fluoroquinolone antibiotic which is used to treat mild to severe life-threatening bacterial infections or bacterial infections that have failed to respond to other antibiotic classes.

Levofloxacin injections can be used to treat bacterial infections including respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, endocarditis, meningitis, pelvic inflammatory disease and traveller's diarrhea.

The shares of the company were traded at Rs 337 on the Bombay Stock Exchange (BSE) in late afternoon trade today, which were down 0.21% from their previous close.